Nanoparticle Mediated Drug Delivery of Rolipram to Tyrosine Kinase B Positive Cells in the Inner Ear with Targeting Peptides and Agonistic Antibodies

AimSystemic pharmacotherapies have limitation due to blood-labyrinth barrier, so local delivery via the round window membrane opens a path for effective treatment. Multifunctional nanoparticle (NP) mediated cell specific drug delivery may enhance efficacy and reduce side effects. Different NPs with...

Full description

Bibliographic Details
Main Authors: Rudolf eGlueckert, Christian Oliver Pritz, Soumen eRoy, Jozsef eDudas, Anneliese eSchrott-Fischer
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-05-01
Series:Frontiers in Aging Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnagi.2015.00071/full
id doaj-cdaf301313bc482ab52df049d12a9194
record_format Article
spelling doaj-cdaf301313bc482ab52df049d12a91942020-11-24T22:46:12ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652015-05-01710.3389/fnagi.2015.00071137650Nanoparticle Mediated Drug Delivery of Rolipram to Tyrosine Kinase B Positive Cells in the Inner Ear with Targeting Peptides and Agonistic AntibodiesRudolf eGlueckert0Rudolf eGlueckert1Christian Oliver Pritz2Christian Oliver Pritz3Soumen eRoy4Jozsef eDudas5Anneliese eSchrott-Fischer6Medical University of InnsbruckUniversity Clinics of InnsbruckMedical University of InnsbruckHebrew University of JerusalemNational Institute on Deafness and Other Communication Disorders, Division of Intramural Research, National Institutes of HealthMedical University of InnsbruckMedical University of InnsbruckAimSystemic pharmacotherapies have limitation due to blood-labyrinth barrier, so local delivery via the round window membrane opens a path for effective treatment. Multifunctional nanoparticle (NP) mediated cell specific drug delivery may enhance efficacy and reduce side effects. Different NPs with ligands to target TrkB receptor were tested. Distribution, uptake mechanisms, trafficking, and bioefficacy of drug release of rolipram loaded NPs were evaluated.Methods We tested lipid based nanocapsules (LNCs), Quantum Dot, silica NPs with surface modification by peptides mimicking TrkB or TrkB activating antibodies. Bioefficacy of drug release was tested with rolipram loaded LNCs to prevent cisplatin induced apoptosis. We established different cell culture models with SH-SY-5Y and inner ear derived cell lines and used neonatal and adult mouse explants. Uptake and trafficking was evaluated with FACS and confocal as well as transmission electron microscopy. ResultsPlain NPs show some selectivity in uptake related to the in-vitro system properties, carrier material and NP size. Some peptide ligands provide enhanced targeted uptake to neuronal cells but failed to show this in cell cultures. Agonistic antibodies linked to silica NPs showed TrkB activation and enhanced binding to inner ear derived cells. Rolipram loaded LNCs proved as effective carriers to prevent cisplatin induced apoptosis.DiscussionMost NPs with targeting ligands showed limited effects to enhance uptake. NP aggregation and unspecific binding may change uptake mechanisms and impair endocytosis by an overload of NPs. This may affect survival signaling. NPs with antibodies activate survival signaling and show effective binding to TrkB positive cells but needs further optimization for specific internalization. Bioefficiacy of rolipram release confirms LNCs as encouraging vectors for drug delivery of lipophilic agents to the inner ear with ideal release characteristics independent of endocytosis.http://journal.frontiersin.org/Journal/10.3389/fnagi.2015.00071/fullApoptosis Regulatory ProteinsDrug Delivery SystemsRolipramBDNFdrug delivery carrierstargeted therapy
collection DOAJ
language English
format Article
sources DOAJ
author Rudolf eGlueckert
Rudolf eGlueckert
Christian Oliver Pritz
Christian Oliver Pritz
Soumen eRoy
Jozsef eDudas
Anneliese eSchrott-Fischer
spellingShingle Rudolf eGlueckert
Rudolf eGlueckert
Christian Oliver Pritz
Christian Oliver Pritz
Soumen eRoy
Jozsef eDudas
Anneliese eSchrott-Fischer
Nanoparticle Mediated Drug Delivery of Rolipram to Tyrosine Kinase B Positive Cells in the Inner Ear with Targeting Peptides and Agonistic Antibodies
Frontiers in Aging Neuroscience
Apoptosis Regulatory Proteins
Drug Delivery Systems
Rolipram
BDNF
drug delivery carriers
targeted therapy
author_facet Rudolf eGlueckert
Rudolf eGlueckert
Christian Oliver Pritz
Christian Oliver Pritz
Soumen eRoy
Jozsef eDudas
Anneliese eSchrott-Fischer
author_sort Rudolf eGlueckert
title Nanoparticle Mediated Drug Delivery of Rolipram to Tyrosine Kinase B Positive Cells in the Inner Ear with Targeting Peptides and Agonistic Antibodies
title_short Nanoparticle Mediated Drug Delivery of Rolipram to Tyrosine Kinase B Positive Cells in the Inner Ear with Targeting Peptides and Agonistic Antibodies
title_full Nanoparticle Mediated Drug Delivery of Rolipram to Tyrosine Kinase B Positive Cells in the Inner Ear with Targeting Peptides and Agonistic Antibodies
title_fullStr Nanoparticle Mediated Drug Delivery of Rolipram to Tyrosine Kinase B Positive Cells in the Inner Ear with Targeting Peptides and Agonistic Antibodies
title_full_unstemmed Nanoparticle Mediated Drug Delivery of Rolipram to Tyrosine Kinase B Positive Cells in the Inner Ear with Targeting Peptides and Agonistic Antibodies
title_sort nanoparticle mediated drug delivery of rolipram to tyrosine kinase b positive cells in the inner ear with targeting peptides and agonistic antibodies
publisher Frontiers Media S.A.
series Frontiers in Aging Neuroscience
issn 1663-4365
publishDate 2015-05-01
description AimSystemic pharmacotherapies have limitation due to blood-labyrinth barrier, so local delivery via the round window membrane opens a path for effective treatment. Multifunctional nanoparticle (NP) mediated cell specific drug delivery may enhance efficacy and reduce side effects. Different NPs with ligands to target TrkB receptor were tested. Distribution, uptake mechanisms, trafficking, and bioefficacy of drug release of rolipram loaded NPs were evaluated.Methods We tested lipid based nanocapsules (LNCs), Quantum Dot, silica NPs with surface modification by peptides mimicking TrkB or TrkB activating antibodies. Bioefficacy of drug release was tested with rolipram loaded LNCs to prevent cisplatin induced apoptosis. We established different cell culture models with SH-SY-5Y and inner ear derived cell lines and used neonatal and adult mouse explants. Uptake and trafficking was evaluated with FACS and confocal as well as transmission electron microscopy. ResultsPlain NPs show some selectivity in uptake related to the in-vitro system properties, carrier material and NP size. Some peptide ligands provide enhanced targeted uptake to neuronal cells but failed to show this in cell cultures. Agonistic antibodies linked to silica NPs showed TrkB activation and enhanced binding to inner ear derived cells. Rolipram loaded LNCs proved as effective carriers to prevent cisplatin induced apoptosis.DiscussionMost NPs with targeting ligands showed limited effects to enhance uptake. NP aggregation and unspecific binding may change uptake mechanisms and impair endocytosis by an overload of NPs. This may affect survival signaling. NPs with antibodies activate survival signaling and show effective binding to TrkB positive cells but needs further optimization for specific internalization. Bioefficiacy of rolipram release confirms LNCs as encouraging vectors for drug delivery of lipophilic agents to the inner ear with ideal release characteristics independent of endocytosis.
topic Apoptosis Regulatory Proteins
Drug Delivery Systems
Rolipram
BDNF
drug delivery carriers
targeted therapy
url http://journal.frontiersin.org/Journal/10.3389/fnagi.2015.00071/full
work_keys_str_mv AT rudolfeglueckert nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT rudolfeglueckert nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT christianoliverpritz nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT christianoliverpritz nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT soumeneroy nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT jozsefedudas nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT annelieseeschrottfischer nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
_version_ 1725685845403369472